In this episode of Curie, we dive into the early but extraordinary results from two CAR-T cell therapy trials that are rewriting what’s possible for glioblastoma—a brain cancer with a devastating prognosis. Andrew takes you through new data from Mass General and the University of Pennsylvania, where some patients have not just responded, but are alive and well nearly two years after treatment.

With quotes from top researchers like Dr. Bryan Choi and Dr. Stephen Bagley, we explore how this groundbreaking treatment works, why a few patients are experiencing durable remissions, and what hurdles remain before CAR-T can become a viable option for more people with this lethal disease.

Is glioblastoma finally meeting its match? Tune in to find out.